Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9348733 | 1.00 | POLB (0.59) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17363420 | 1.00 | POLB (0.59) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL8574394 | 0.78 | USP2 (0.56) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15922602 | 0.77 | HPGD (0.71) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15922601 | 0.77 | HPGD (0.71) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10693185 | 0.76 | ALDH1A1 (0.57) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL8324607 | 0.76 | MTNR1A (0.71) | POLBNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL30518933 | 0.74 | MTNR1A (0.64) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11092496 | 0.74 | RAB9A (1.00) | POLBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6396790 | 0.74 | RAB9A (0.76) | POLBNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253032-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-2951186-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180155354-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-07 | — | — | US | disclosed |
| US-20180155354-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-07 | — | — | US | disclosed |
| US-9738650-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738650-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150376195-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-31 | — | — | US | disclosed |
| US-20150376195-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-31 | — | — | US | disclosed |
| EP-2951186-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120789-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120789-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253032-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | POLB 4447/4885NPC1 1322/4885RAB9A 1183/4885 |
| US-20150376195-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | POLB 4447/4885NPC1 1322/4885RAB9A 1183/4885 |
| US-20180155354-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | POLB 4447/4885NPC1 1322/4885RAB9A 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.